World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
56
Citations
14974
World Ranking
3668
National Ranking
1440

Overview

Tami Pilot-Matias is affiliated with AbbVie in the United States and has a substantial body of research primarily within the field of Medicine. Their work notably spans across subfields such as Epidemiology, Hepatology, Infectious Diseases, Genetics, and Pediatrics, Perinatology, and Child Health.

Their research focuses on several key topics, including:

  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • HIV/AIDS drug development and treatment
  • Liver Diseases and Immunity
  • Childhood Cancer Survivors' Quality of Life

Among the recent papers associated with Tami Pilot-Matias are:

  • "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials" (2020) published in Journal of Hepatology
  • "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study" (2020) published in The Lancet. Gastroenterology & Hepatology
  • "Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study" (2020) published in CMAJ Open
  • "Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study" (2021) published in Journal of Viral Hepatitis
  • "Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)" (2021) published in npj Vaccines

Frequent co-authors in the scientist's research output include:

  • Alnoor Ramji
  • Hin Hin Ko
  • Scott Fung
  • Curtis Cooper
  • Carla S. Coffin

The publications appear regularly in specific academic venues such as:

  • Journal of Hepatology
  • Canadian Liver Journal
  • The American Journal of Gastroenterology
  • Gastroenterology
  • The Lancet. Gastroenterology & Hepatology

Best Publications

  • ISOLATION OF NOVEL VIRUS-LIKE SEQUENCES ASSOCIATED WITH HUMAN HEPATITIS

    J N Simons;T P Leary;G J Dawson;T J Pilot-Matias

  • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

    Jordan J. Feld;Kris V. Kowdley;Eoin Coakley;Samuel Sigal

  • Identification of two flavivirus-like genomes in the GB hepatitis agent.

    J N Simons;T J Pilot-Matias;T P Leary;G J Dawson

  • Sequence and genomic organization of GBV‐C: A novel member of the flaviviridae associated with human non‐A‐E hepatitis

    Leary Tp;Muerhoff As;Simons Jn;Pilot-Matias Tj

  • Molecular and biophysical characterization of TT virus: Evidence for a new virus family infecting humans

    Mushahwar Ik;Erker Jc;Muerhoff As;Leary Tp

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

    Paul Y. Kwo;Parvez S. Mantry;Eoin Coakley;Helen S. Te

  • Exploratory study of oral combination antiviral therapy for hepatitis C

    Fred Poordad;Eric Lawitz;Kris V. Kowdley;Daniel E. Cohen

  • Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial

    Mark S. Sulkowski;Joseph J. Eron;David Wyles;Roger Trinh

  • Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

    Christophe Hézode;Tarik Asselah;K Rajender Reddy;Tarek Hassanein

  • Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis.

    A S Muerhoff;T P Leary;J N Simons;T J Pilot-Matias

  • Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

    Kris V. Kowdley;Eric Lawitz;Fred Poordad;Daniel E. Cohen

  • Hepatitis C virus drug resistance–associated substitutions: State of the art summary

    Erik Lontok;Patrick Harrington;Anita Howe;Tara Kieffer

  • Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

    Liangjun Lu;Tami J. Pilot-Matias;Kent D. Stewart;John T. Randolph

  • Molecular and serologic analysis in the transmission of the GB hepatitis agents

    G G Schaluder;G J Dawson;J N Simons;T J Pilot-Matias

  • Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction.

    George J. Dawson;George G. Schlauder;Tami J. Pilot-Matias;Dwain L Thiele

  • Sequence heterogeneity within the 5′-terminal region of the hepatitis GB virus C genome and evidence for genotypes

    A.Scott Muerhoff;John N. Simons;Thomas P. Leary;James C. Erker

  • Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

    Hiromitsu Kumada;Kazuaki Chayama;Lino Rodrigues;Fumitaka Suzuki

  • Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology

    Teresa I. Ng;Hongmei Mo;Tami Pilot-Matias;Yupeng He

  • In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

    Preethi Krishnan;Jill Beyer;Neeta Mistry;Gennadiy Koev

  • Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.

    David Wyles;Fred Poordad;Stanley Wang;Laurent Alric

Frequent Co-Authors

Isa K. Mushahwar
Isa K. Mushahwar Abbott (United Kingdom)
Christophe Hézode
Christophe Hézode Université Paris Cité
Hiromitsu Kumada
Hiromitsu Kumada Fukuoka University
Kazuaki Chayama
Kazuaki Chayama Hiroshima University
Stanislas Pol
Stanislas Pol Université Paris Cité
Graham R. Foster
Graham R. Foster Queen Mary University of London
Hongmei Mo
Hongmei Mo Gilead Sciences (United States)
Fumitaka Suzuki
Fumitaka Suzuki Toranomon Hospital
Tarik Asselah
Tarik Asselah Université Paris Cité
Kris V. Kowdley
Kris V. Kowdley Washington State University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can open a range of opportunities for those interested in Microbiology and allied fields. For example, many students opt for an online public health masters programs easy to get into to expand their expertise in epidemiology and global health, often complementing their science background.

Certification is another critical step in career advancement. Those drawn to pediatric care might consider the ccls certification, which prepares professionals to support children’s emotional well-being during medical procedures. This diverse credential can offer fulfilling job prospects beyond traditional lab roles.

For individuals with unique circumstances, there are inclusive opportunities as well. Several online colleges that accept felons provide pathways to education and professional development, making it clear that a past record does not have to hinder a promising career in science or healthcare.

Lastly, an emerging field combining healthcare and holistic practices is functional medicine nursing. Becoming a functional medicine np offers specialized training that integrates traditional biology with natural treatments, suitable for those passionate about innovative patient care.

Best Scientists Citing Tami Pilot-Matias

Trending Scientists

Recently Published Articles